PMID- 30113568 OWN - NLM STAT- MEDLINE DCOM- 20190917 LR - 20191015 IS - 1897-9483 (Electronic) IS - 0032-3772 (Linking) VI - 128 IP - 11 DP - 2018 Nov 30 TI - Functional status with rhythm- versus rate-control strategy for persistent atrial fibrillation. PG - 658-666 LID - 10.20452/pamw.4316 [doi] AB - Introduction Recent studies have shown that rhythm control does not provide additional benefit over rate control in terms of morbidity or mortality and is less cost effective in patients with atrial fibrillation (AF). It remains to be determined if any of the treatment strategies should be favored on the basis of the quality of life (QoL) or functional capacity. Objectives This HOT CAFE substudy was conducted to compare the functional status of patients with persistent AF assigned either to rate or rhythm control strategy. Patients and methods We enrolled 205 patients (mean [SD] age, 60.8 [11.2] years) with persistent AF who were randomly assigned either to rate or rhythm control strategies. The New York Heart Association (NYHA) functional classification, intensity of arrhythmia‑related symptoms, exercise tolerance, and QoL were analyzed. Results After a mean (SD) of 1.7 (0.4) years, the NYHA class and QoL improved in both groups. Both strategies lead to improvement in AF‑related symptoms. Treadmill test duration and maximal workload increased over time in both groups. In terms of NYHA class improvement, rhythm control was superior to rate control in patients with AF and hypertension (odds ratio [OR], 1.89; 95% CI, 0.98-3.65; P = 0.055) and in those with moderate HF (OR, 2.04; 95% CI, 1.03-4.06; P = 0.04). When success was considered as left ventricular function improvement, the rhythm‑control strategy also proved to be superior in patients with hypertension (OR, 2.64; 95% CI, 1.21-5.74; P = 0.01) and those with NYHA class II or III (OR, 4.27; 95% CI, 1.25-9.85; P <0.001). Conclusions Rate- and rhythm‑control strategies improved functional status in patients with persistent AF. However, rhythm control might be more appropriate for patients with AF and hypertension and those with moderate HF. FAU - Kosior, Dariusz A AU - Kosior DA FAU - Szulc, Marcin AU - Szulc M FAU - Rosiak, Marek AU - Rosiak M FAU - Rabczenko, Daniel AU - Rabczenko D FAU - Opolski, Grzegorz AU - Opolski G FAU - For The Investigators Of The Hot Cafe Polish Study AU - For The Investigators Of The Hot Cafe Polish Study LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20180816 PL - Poland TA - Pol Arch Intern Med JT - Polish archives of internal medicine JID - 101700960 RN - 0 (Anti-Arrhythmia Agents) SB - IM CIN - Pol Arch Intern Med. 2018 Nov 30;128(11):638-643. PMID: 30504753 MH - Adult MH - Aged MH - Anti-Arrhythmia Agents/*therapeutic use MH - Atrial Fibrillation/*physiopathology/*therapy MH - Electric Countershock/*methods MH - Exercise Test MH - Female MH - Hemodynamics MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - Quality of Life MH - Treatment Outcome MH - Ventricular Function, Left EDAT- 2018/08/17 06:00 MHDA- 2019/09/19 06:00 CRDT- 2018/08/17 06:00 PHST- 2018/08/17 06:00 [pubmed] PHST- 2019/09/19 06:00 [medline] PHST- 2018/08/17 06:00 [entrez] AID - 10.20452/pamw.4316 [doi] PST - ppublish SO - Pol Arch Intern Med. 2018 Nov 30;128(11):658-666. doi: 10.20452/pamw.4316. Epub 2018 Aug 16.